New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
08:04 EDTAGIOAgios initiates AG-348 Phase 1 study
Agios Pharmaceuticals announced dose administration of AG-348 in a Phase 1 study in healthy volunteers. AG-348 is an orally available, potent, selective small molecule activator of pyruvate kinase-R, a metabolic enzyme, which, when mutated, leads to pyruvate kinase deficiency, a rare, inherited hemolytic anemia. AG-348 is wholly owned by Agios, with the company maintaining full worldwide development and commercialization rights. The company said, “Preclinical studies have demonstrated that AG-348 activates a broad spectrum of PK-R mutant proteins, and corrects the metabolic defects found in patient-derived blood samples. These data support the hypothesis that drug intervention with AG-348 will restore glycolytic pathway flux and normalize red blood cell metabolism. Because AG-348 directly targets the underlying disease, it has the potential to be an important treatment option for patients with PK deficiency.”
News For AGIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
15:06 EDTAGIOAgios Pharmaceuticals announces orphan drug designation of AG-348
Subscribe for More Information
14:03 EDTAGIOAgios pyruvate kinase deficiency treatment granted FDA orphan status
The FDA designated an allosteric activator of the red blood cell-specific form of pyruvate kinase from Agios Pharmaceuticals as an orphan treatment of pyruvate kinase deficiency, the FDA stated in a post to its site. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use